Cagrilintide + Semaglutide (CagriSema)

Fixed dual combination of long-acting amylin analog + GLP-1 agonist for enhanced weight loss.

Quick Reference

Dose: Typically escalate both to 2.4 mg each
Frequency / schedule: Once weekly
Route: Subcutaneous
Timing: Same day each week
Fasting: Not required
Cycle: 68+ weeks in trials or ongoing
Time off: Weight regain expected on stop

How this works

Combines amylin receptor activation (satiety + delayed gastric emptying) with GLP-1 receptor activation (appetite suppression + glucose control). The two pathways are complementary, producing additive weight-loss effects in Phase 3 trials.

Benefits + side effects

Potential Benefits

Greater average weight loss than semaglutide or cagrilintide monotherapy
Strong glycemic improvements

Side Effects

Higher incidence of GI effects than monotherapy (still mostly mild–moderate)

Dosing / Protocol

Reference Protocol

Phase / week	Dose	Frequency	Timing	Notes
Titrate each component (or fixed combination) over several weeks to 2.4 mg cagrilintide + 2.4 mg semaglutide once weekly.

Timing + Fasting Notes

Same day each week. Flexible with food.

Practical Reference

Storage: Refrigerated reconstituted
Route / injection context: Subcutaneous
Cycle / time off: 68+ weeks in trials or ongoing · Weight regain expected on stop
Practical notes: Research / investigational combination. Monitor GI tolerability closely.

References

Coadministered Cagrilintide and Semaglutide in Adults with Overweight or ObesityNew England Journal of Medicine · 2025

CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.

Search Femetric